Objectives: The aim of this study was to compare the anesthetic and analgesic effects of prilocaine alone, prilocaine added dexketoprofen and dexamethasone during intravenous regional anesthesia (IVRA).
Methods: Forty five patients undergoing forearm or hand surgery were randomly assigned to one of three groups to receive (Group P) 3 mg/kg 0.5% prilocaine; (Group PDK) 3 mg/kg 0.5% prilocaine plus 50 mg dexketoprofen; (Group PDM) 3 mg/kg 0.5% prilocaine plus 8 mg dexamethasone in total 40 ml volume for IVRA. The onset and duration of sensory and motor blocks, hemodynamic datas, duration of analgesia and tourniquet, time to first analgesic requirement, visual analog scale (VAS), total analgesic consumption in 24 hours and patient satisfaction score were assessed and recorded.
Results: Time to onset of sensory block was found to be longer in Group P (p<0.05), though no significance was found according to sensory block recovery times amoung groups. Time to onset of motor block was found to be longer and recovery time of motor block was found to be shorter in Group P (p<0.05). Time to first analgesic requirement was found to be longer in Group PDK,and was found to be high in Group PDM than Group PDK(p<0.05). The VAS scores was found to be high and patient satisfaction scale was found to be low in Group P (p<0.05).
Conclusion: The addition of dexketoprofen and dexamethasone to prilocaine during IVRA improves the quality of both anesthesia and analgesia moreover dexketoprofen provides beter postoperative analgesia during the first 24 hour after surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5505/agri.2014.93064 | DOI Listing |
Background: XPro1595 (XPro) is a brain-penetrant, recombinant protein variant of human tumor necrosis factor (TNF) rationally designed to selectively neutralize only the soluble, pro-inflammatory form of the cytokine (solTNF). An unbiased proteomic analysis of CSF samples from an open-label, phase-1b study (NCT03943264) in patients with Alzheimer's disease (AD) was conducted to assess for pharmacodynamic activity and disease-specific target engagement.
Method: Patients with AD (n = 20) were treated for 12-weeks with one of three doses of XPro: 0.
Alzheimers Dement
December 2024
University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Background: Many lines of evidence support that systemic inflammation promotes Alzheimer's disease (AD) progression. Amyloid plaques are closely accompanied with neuroinflammation characterized by activated microglia and reactive astrocytes. Aging is the largest known risk factor for AD and is characterized by chronic, systemic, low-grade inflammation (inflamm-aging).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: The U.S. Population is older today than it has ever been.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurology Department, Duke University, Durham, NC, USA.
Background: APOE4 leads to increased neuroinflammation, neurocognitive decline, increased risk of Alzheimer's disease, and may be associated with increased delirium risk. However, the safety and feasibility of pharmacologic modulation of APOE to prevent neuroinflammation and postoperative delirium is unclear.
Methods: We performed a Phase II, triple blind, escalating dose, randomized controlled trial to determine the safety, feasibility, and efficacy of the APOE mimetic peptide CN-105 for preventing postoperative neuroinflammation and delirium.
Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!